Cure8 research brief
Older adults with IBD and other immune-mediated diseases often face different safety risks from advanced therapies.
This review summarizes pooled evidence suggesting JAK inhibitors raise infection risk in older patients while IL-12/23 and IL-23 agents may have lower serious infection risk compared with anti-TNF drugs; thromboembolism signals may vary by disease type.
Older adult patients with IBD or other immune-mediated inflammatory diseases, clinicians prescribing advanced therapies, and researchers studying drug safety in older populations.
This paper is a systematic review and meta-analysis of studies reporting safety outcomes for JAK inhibitors and anti–IL-12/23 and IL-23 agents in older adults with immune-mediated inflammatory diseases, including IBD.
The authors pooled results across conditions and compared older patients on these advanced therapies to younger patients, to older patients on non-advanced therapies, or to older patients on different advanced therapies.
Key findings reported in the abstract: pooled data showed JAK inhibitors were associated with higher odds of infections and serious infections in older patients overall, while anti–IL-12/23 and IL-23 agents had lower odds of serious infections compared with anti-TNF therapies.
No overall increase in major adverse cardiovascular events, venous thromboembolism, malignancy, or mortality was observed, but a higher VTE signal with JAK inhibitors appeared in rheumatology cohorts and not in IBD cohorts. This brief is based on the article abstract provided by the journal; Cure8 did not review the full paper beyond the supplied abstract.
This classification is grounded in the article abstract (systematic review/meta-analysis). The abstract reports pooled associations but does not present full trial-level details or individual patient data here. Disease-specific differences (IBD vs rheumatology) were noted for VTE risk; consult the full paper or your clinician for treatment decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
